A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center revealed that common breast cancer treatments, including chemotherapy, radiation, and surgery, may accelerate the biological aging process in breast cancer survivors.
Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
Research from the University of California, Irvine revealed how disruption of the circadian clock may accelerate the progression of colorectal cancer by affecting the gut microbiome and intestinal barrier function.
New data validated a multimodal artificial intelligence-based biomarker’s ability to help inform treatment decisions for patients with oligometastatic castration-sensitive prostate cancer, including metastasis-directed therapy benefit.
A novel analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, according to a study from researchers at Weill Cornell Medicine and the New York Genome Center.
The recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the phase III OnTarget trial indicate that crofelemer (Mytesi, Fulyzaq) achieved statistical significance in this subgroup.
A study by scientists at the University of Texas Health Science Center at San Antonio provides one of the first models to study the progression of normal human pancreatic cells toward tumor cells.
A pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a study published Sept. 30 in the journal Cell.
Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, has expanded its collaboration with AmplifyBio, a rapidly growing contract development and manufacturing organization, through the installation of a new AVATAR Foundry system as part of Xcellbio’s beta access program.
AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses across patients with MTAP-deleted solid tumors, as well as an acceptable safety profile, according to first-in-human results of a dose-exploration/dose-expansion phase I study (NCT05094336) that were presented at the 2024 ESMO Congress.
